| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1061 | 2019 |
| Bi-directional analysis between fatty liver and cardiovascular disease risk factors J Ma, SJ Hwang, A Pedley, JM Massaro, U Hoffmann, RT Chung, ... Journal of hepatology 66 (2), 390-397, 2017 | 220 | 2017 |
| Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease J Ma, R Hennein, C Liu, MT Long, U Hoffmann, PF Jacques, ... Gastroenterology 155 (1), 107-117, 2018 | 167 | 2018 |
| AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review MT Long, M Noureddin, JK Lim Gastroenterology 163 (3), 764-774. e1, 2022 | 130 | 2022 |
| Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes JF O’Sullivan, JE Morningstar, Q Yang, B Zheng, Y Gao, S Jeanfavre, ... The Journal of clinical investigation 127 (12), 4394-4402, 2017 | 124 | 2017 |
| Female authorship in major academic gastroenterology journals: a look over 20 years MT Long, A Leszczynski, KD Thompson, SK Wasan, AH Calderwood Gastrointestinal endoscopy 81 (6), 1440-1447. e3, 2015 | 119 | 2015 |
| Visceral and intrahepatic fat are associated with cardiometabolic risk factors above other ectopic fat depots: the Framingham Heart Study JJ Lee, A Pedley, U Hoffmann, JM Massaro, D Levy, MT Long The American journal of medicine 131 (6), 684-692. e12, 2018 | 115 | 2018 |
| Administrative coding in electronic health care record‐based research of NAFLD: an expert panel consensus statement H Hagström, LA Adams, AM Allen, CD Byrne, Y Chang, H Grønbæk, ... Hepatology 74 (1), 474-482, 2021 | 114 | 2021 |
| Nonalcoholic fatty liver disease and obesity treatment KT Brunner, CJ Henneberg, RM Wilechansky, MT Long Current obesity reports 8, 220-228, 2019 | 114 | 2019 |
| Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis MT Long, A Pedley, LD Colantonio, JM Massaro, U Hoffmann, P Muntner, ... Clinical Gastroenterology and Hepatology 14 (8), 1172-1180. e2, 2016 | 110 | 2016 |
| Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality KJ Rosenquist, JM Massaro, A Pedley, MT Long, BE Kreger, RS Vasan, ... The Journal of Clinical Endocrinology & Metabolism 100 (1), 227-234, 2015 | 96 | 2015 |
| A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation M Vujkovic, S Ramdas, KM Lorenz, X Guo, R Darlay, HJ Cordell, J He, ... Nature genetics 54 (6), 761-771, 2022 | 88 | 2022 |
| Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study MT Long, N Wang, MG Larson, GF Mitchell, J Palmisano, RS Vasan, ... Arteriosclerosis, thrombosis, and vascular biology 35 (5), 1284-1291, 2015 | 86 | 2015 |
| Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study J Cui, CH Chen, MT Lo, N Schork, R Bettencourt, MP Gonzalez, A Bhatt, ... Hepatology 64 (5), 1547-1558, 2016 | 83 | 2016 |
| The Framingham Heart Study—67 years of discovery in metabolic disease MT Long, CS Fox Nature Reviews Endocrinology 12 (3), 177-183, 2016 | 80 | 2016 |
| Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the Framingham heart study ZP Fricker, A Pedley, JM Massaro, RS Vasan, U Hoffmann, EJ Benjamin, ... Clinical Gastroenterology and Hepatology 17 (6), 1157-1164. e4, 2019 | 78 | 2019 |
| Upper body subcutaneous fat is associated with cardiometabolic risk factors JJ Lee, A Pedley, KE Therkelsen, U Hoffmann, JM Massaro, D Levy, ... The American journal of medicine 130 (8), 958-966. e1, 2017 | 73 | 2017 |
| Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis WT Kimberly, JF O’Sullivan, AK Nath, M Keyes, X Shi, MG Larson, Q Yang, ... JCI insight 2 (9), 2017 | 70 | 2017 |
| Clonal haematopoiesis and risk of chronic liver disease WJ Wong, C Emdin, AG Bick, SM Zekavat, A Niroula, JP Pirruccello, ... Nature 616 (7958), 747-754, 2023 | 66 | 2023 |
| Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the Framingham heart study MT Long, X Zhang, H Xu, CT Liu, KE Corey, RT Chung, R Loomba, ... Hepatology 73 (2), 548-559, 2021 | 62 | 2021 |
